Zomato Ltd has launched Nugget, an AI-native customer support platform to automate and streamline business interactions. Announced by co-founder and Group CEO Deepinder Goyal on February 17, the platform is built as a no-code tool that businesses can use without needing a dedicated development team.

Built as an Internal Tool

Nugget was initially developed for Zomato, Blinkit, and Hyperpure over three years. It currently handles over 15 million support interactions per month across these platforms. According to the company, the system can resolve up to 80% of customer queries autonomously by learning and adapting over time.

Features and Functionality

The platform is to handle a range of customer support tasks, including:

• Automated query resolution without manual intervention
• AI-powered analytics and quality audits
• Integration with tools like Freshdesk and Zoho
• Support for chat and voice interactions
• A co-pilot feature for human agents, which reportedly improves compliance by 25%
• Reduction in resolution time by 20%

Expansion Beyond Zomato

After using Nugget internally, Zomato has decided to make it available to businesses globally. Goyal mentioned that 90% of companies that have tested the platform have signed up. To encourage more businesses to adopt the tool, Zomato is offering it free of charge for companies locked into contracts with existing providers.

Zomato’s Recent Developments

The launch of Nugget follows Zomato’s recent decision to rename itself as Eternal Ltd. This change shows Blinkit’s increasing role in the company’s overall business strategy.

Zomato’s recent financial results showed a 57% year-on-year decline in net profit to ₹59 crore in Q3FY25. However, its revenue from operations increased by 64% year-on-year, reaching ₹5,404 crore.

Zomato Ltd is trading at ₹218.78, up 0.11% today (Feb 18, 12:20 PM), though it has declined 8.75% over the past month but remains 38.91% higher year-on-year.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. \

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Anant Raj Ltd has entered into an agreement with CSC Data Services India Ltd (CDSIL), a subsidiary of CSC E-Governance Services India Ltd. The partnership focuses on providing rack rental (co-location data centres) and cloud services to government departments and private organisations.

Details of the Agreement

Under this agreement, Anant Raj Cloud Pvt. Ltd (ARC), a 100% subsidiary of Anant Raj Ltd, will offer technical, technology, and marketing support to CDSIL. The collaboration also includes implementing sovereign data centre services and disaster recovery solutions.

About CSC Data Services India Ltd

CDSIL is a subsidiary of CSC E-Governance Services India Ltd, which operates under the National e-Governance Plan of the Government of India. The company provides data centre services, web hosting, IT and ITES, and turnkey solutions, primarily serving government entities and departments.

Market Reaction 

Following the announcement on Feb 17, Anant Raj’s stock closed at ₹520.35 on the BSE, down ₹34.50 or 6.22%. However, in early trade today,  on February 18, 2025, the stock saw an initial increase of 3%, reaching ₹534.35 but was later trading at ₹495.75, down 4.49% (-₹23.30) as of Feb 18, 12:31 PM. Over the past year, the stock has gained more than 50%, with a 52-week high of ₹947.25 and a low of ₹281.15.

Financial Performance

For the December quarter, Anant Raj Ltd reported a net profit of ₹110.32 crore, showing a 53.58% year-on-year increase. Revenue rose by 36.29% to ₹534.64 crore compared to the same period last year.

As per the filing, the agreement focuses on expanding data infrastructure in India. It provides Anant Raj with an entry into the data centre business while CDSIL gains additional support for its services. The impact of this partnership will depend on how effectively both companies implement the agreement and secure clients.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Shares of Uno Minda rose 2% to ₹909 in early trade on February 18, reversing a three-day losing streak. The increase followed the company’s announcement of a joint venture with Suzhou Inovance Automotive Co. Ltd and its subsidiary, Inovance Automotive (HK) Investment Co. Ltd. 

The stock had declined over 8% in the past week and 17% in the last month.

Details of the Joint Venture

Uno Minda Auto Innovations Private, a wholly owned subsidiary of Uno Minda, will be converted into a joint venture. Inovance Automotive (HK) Investment Co. will acquire a 30% stake, while Uno Minda will hold the remaining 70%. 

The venture will focus on manufacturing high-voltage EV powertrain components, including combined charging units, E-axles, inverters, and motors.

Manufacturing and Governance

The joint venture will operate in India, with products sold under both Uno Minda and Inovance Automotive brands. It will have an eight-member board, five appointed by Uno Minda, including the chairman, and three by Inovance Automotive. Governance provisions include share transfer restrictions, board representation rights, and regulations related to capital structure changes.

Previous Agreement 

Uno Minda had previously signed a technical license agreement with Inovance Automotive in June 2024. The new joint venture builds on that arrangement, expanding collaboration between the companies in the EV powertrain segment.

Financial Performance

Uno Minda reported a 20% increase in net profit year-on-year, reaching ₹157 crore from ₹131 crore. Revenue also rose 20% to ₹3,136 crore, compared to ₹2,611 crore in the same quarter last year. EBITDA stood at ₹301 crore, with margins declining slightly to 9.6% from 10.2% in the previous year.

At 9:40 am, Uno Minda’s stock was trading at ₹900, up 1.2% from the last close on the NSE.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Krishna Institute of Medical Sciences Ltd (KIMS) has entered into an operations and management agreement with Ushahkal Abhinav Institute of Medical Sciences (UAIMS) Hospital in Sangli, Maharashtra. The agreement is for an initial period of seven years, with an option to extend it by another three years. 

KIMS will handle the hospital’s management and service operations while retaining exclusive rights over its medical services.

Expansion Plans

UAIMS Hospital, established in 2022, is a quaternary care facility with 316 beds. It has plans to expand beyond 500 beds in the future. The hospital is equipped with CT and MRI facilities, 15 operation theatres, and a mother and child care unit occupying an entire floor. UAIMS has over 100 critical care beds.

As per the filling, a daycare oncology centre is also under development near the hospital. It is expected to be completed and become operational in 2025.

Financial Terms and Rights

As per the agreement, KIMS will receive 9% of UAIMS Hospital’s net revenue. KIMS and its affiliates will also have the first right of refusal (ROFR) to acquire profit-sharing interests from existing partners during the contract period. Additionally, KIMS has a call option to acquire a majority profit share in UAIMS at its discretion.

KIMS’ in Maharashtra

KIMS has been expanding its presence in Maharashtra in recent years. It acquired Kingsway Hospital in Nagpur in 2022 and started operations at its Nashik hospital in 2024. It has also announced a new 300-bed multi-specialty hospital in Thane, which is to begin operations in the next financial year.

Market Impact

On February 18, 2025, shares of Krishna Institute of Medical Sciences Ltd traded at ₹549.00, down ₹12.25 (2.18%) at 12:47 PM. The stock has declined 11.89% over the past month but remains up 23.11% over the past year.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Biocon Biologics Ltd (BBL), a part of Biocon Ltd, has received marketing approval from the European Commission (EC) for its Ustekinumab biosimilar, YESINTEK. in Europe. This approval enables Biocon to distribute the drug across the European Union (EU), offering an alternative treatment for various inflammatory diseases.

YESINTEK: A New Treatment Option

YESINTEK is a medicine for adults and children with plaque psoriasis and for adults with psoriatic arthritis and Crohn’s disease. Tests have shown that it works just as well and is as safe as the original Ustekinumab drug, making it a good option for patients.

Strengthening Biocon’s Global Position

This milestone reinforces Biocon Biologics’ commitment to providing affordable and high-quality biosimilars worldwide. The company continues to expand its global footprint, leveraging its expertise in biosimilars to improve healthcare accessibility and offer cost-effective treatment options to patients in need.

About Biocon Biologics

Biocon Biologics Ltd is a global company specialising in biosimilars, offering affordable and high-quality medicines for various diseases. As a subsidiary of Biocon Ltd, it focuses on developing and supplying innovative treatments worldwide, improving healthcare access for patients.

Share Performance 

As of February 18, 2025, at 11:10 AM, the shares of Biocon are trading at ₹336.65 per share, down 3.14% from yesterday’s closing price. Over the last month, the stock has declined by 16.16% and over the last year it has fallen by 8.80%. The stock’s 52-week high is ₹404.70 and its low is ₹244.55.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Deepak Fertilisers and Petrochemicals Corporation Ltd (DFPCL) has strengthened its presence in the Australian mining solutions market. On 17 February 2025, its wholly-owned subsidiary, Deepak Mining Solutions Ltd (DMSL), increased its stake in Platinum Blasting Services Pty Ltd from 65% to 85%.

Strategic Investment for Expansion

The transaction, valued at AUD 11.78 million (₹64.1 crore), involved acquiring shares from existing stakeholders. Platinum Blasting Services, a profitable and dividend-paying entity, plays a key role in providing end-to-end mining solutions. This acquisition aligns with DMSL’s long-term strategy of evolving from a commodity-driven model to a full-fledged mining solutions provider.

Valuation and Regulatory Approval

The share purchase was executed based on an earnings multiple valuation, as per guidance from a Big 4 accounting firm in Australia. The deal received formal approval from Platinum Blasting Services Pty Ltd on 17 February 2025 at 1:33 p.m., as confirmed in a stock exchange filing.

Deepak Fertiliser Share Performance

As of February 18, 2025, at 12:55 PM, the shares of Deepak Fertiliser are trading at ₹948.00 per share, down 3.73% from yesterday’s closing price. Over the last month, the stock has declined by 19.30% and over the last year it has surged by 92%. The stock’s 52-week high is ₹1,443.10 and its low is ₹450.00.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

LMEL, a prominent player in the metals and energy sector, has completed a major acquisition by securing a substantial stake in TEIL. This action supports LMEL’s strategic goals for development and broader market reach.

Acquisition Approval

Lloyds Metals and Energy Limited (LMEL) has decided to acquire a majority stake in Thriveni Earthmovers and Infra Private Limited (TEIL). The company will subscribe to 70 crore equity shares, representing 79.82% of TEIL’s total share capital for an investment of ₹70 crore. This step aligns with its growth strategy and expansion plans.  

Company’s Next Steps

With this acquisition, LMEL is set to expand its operations and enhance its capabilities. The strategic move is expected to create synergies, drive growth and contribute to long-term business success. The company remains committed to its vision and industry leadership.  

About the company

Lloyds Metals and Energy Limited (LMEL) is a growing player in the metals and energy sector, focused on expansion, efficiency and transparency. Through strategic investments, the company aims to strengthen its market position and drive long-term growth. 

Share Performance 

As of February 18, 2025, at 12:35 PM, with a market capitalisation of ₹577.19 billion, the shares of LMEL are trading at ₹1,107 per share, down 2.01% from the previous day’s closing price. Over the past month, the stock has registered a loss of 20.71%. The stock’s 52-week high stands at ₹1,478 per share, while its 52-week low is ₹531 per share.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

DCX Systems Limited has recently announced the receipt of multiple domestic and export purchase orders, cumulatively valued at approximately ₹24.51 crores. These orders are part of the company’s routine business operations and signify its growing presence in the defence and aerospace sectors.

Significant Contracts from Defence Giants

The latest orders highlight DCX Systems’ strong business relationships with leading defence and aerospace organisations. Notably, Bharat Electronics Limited (BEL), a premier Indian defence PSU, has placed an order worth ₹9.33 crores for cable and wire harness assemblies. 

Additionally, major international clients, including Rafael Advanced Defence Systems (Israel) and Elbit Systems Ltd (Israel), have collectively contributed to orders exceeding ₹9 crores.

Strengthening Market Position

The procurement of these orders not only reinforces DCX Systems’ credibility in the market but also reflects its capabilities to cater to both domestic and global defence needs. Other key clients such as Alpha-Elsec Defence & Aerospace Systems Pvt. Ltd. and India Optel Limited have also placed significant orders, further bolstering the company’s financial prospects and industry reputation.

DCX Systems Share Performance

As of February 18, 2025, at 2:12 PM, the shares of DCX Systems are trading at ₹242.80 per share, down 3.34% from yesterday’s closing price. Over the last month, the stock has declined by 33.68% and over the last year it has declined by 27.62%. The stock’s 52-week high is ₹451.90 and its low is ₹235.30.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing